Deep Learning in Cancer: Redefining Diagnosis, Prognosis, and Precision Oncology

Updated on: May 28,2025

Deep Learning in Cancer: Redefining Diagnosis, Prognosis, and Precision Oncology

Updated on:May 28,2025

Pembrolizumab Monotherapy Displays Efficacy in Rare Sarcomas

The PD-1 inhibitor pembrolizumab (Keytruda) displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes, according to findings from the phase 2 A

Updated on: November 07,2023

Pembrolizumab Monotherapy Displays Efficacy in Rare Sarcomas

The PD-1 inhibitor pembrolizumab (Keytruda) displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes, according to findings from the phase 2 A

Updated on:November 07,2023

Study reveals a new approach to enhancing response to immunotherapy in melanoma

bySanford Burnham Prebys Medical Discovery InstituteMelanoma in skin biopsy with H&E stain—this case may represent superficial spreading melanoma. Credit: Wikipedia/CC BY-SA 3.0Scientists at

Updated on: December 20,2023

Study reveals a new approach to enhancing response to immunotherapy in melanoma

bySanford Burnham Prebys Medical Discovery InstituteMelanoma in skin biopsy with H&E stain—this case may represent superficial spreading melanoma. Credit: Wikipedia/CC BY-SA 3.0Scientists at

Updated on:December 20,2023

New blood test revolutionizes early cancer detection in Li-Fraumeni Syndrome patients

In a study published inCancer Discovery, researchers from Canada tested the use of a multimodal liquid biopsy assay based on cell-free DNA (cfDNA) for early cancer detection in patients with Li-

Updated on: October 30,2023

New blood test revolutionizes early cancer detection in Li-Fraumeni Syndrome patients

In a study published inCancer Discovery, researchers from Canada tested the use of a multimodal liquid biopsy assay based on cell-free DNA (cfDNA) for early cancer detection in patients with Li-

Updated on:October 30,2023

Localizing BRCA gene mutations to better treat ovarian cancer

byUniversity of GenevaDistribution of mutations in BRCA1 and BRCA2. A. Graphical summary of BRCA1 and BRCA2 mutations. Mutation plot was generated using cBioPortal MutationMapper tool. Black = n

Updated on: December 20,2023

Localizing BRCA gene mutations to better treat ovarian cancer

byUniversity of GenevaDistribution of mutations in BRCA1 and BRCA2. A. Graphical summary of BRCA1 and BRCA2 mutations. Mutation plot was generated using cBioPortal MutationMapper tool. Black = n

Updated on:December 20,2023

Targeting enzyme could alleviate muscle wasting for cancer patients

byUniversity of Texas Health Science Center at HoustonCredit: Pixabay/CC0 Public DomainTargeting a specific enzyme in the muscle could help cancer patients preserve muscle mass and potentially p

Updated on: December 19,2023

Targeting enzyme could alleviate muscle wasting for cancer patients

byUniversity of Texas Health Science Center at HoustonCredit: Pixabay/CC0 Public DomainTargeting a specific enzyme in the muscle could help cancer patients preserve muscle mass and potentially p

Updated on:December 19,2023

Measuring 'quality of life' is an important trend in cancer care

byUniversity of Rochester Medical CenterCredit: Pixabay/CC0 Public DomainAs novel cancer treatments continually emerge, it is essential to collect data on patients' quality of life along wit

Updated on: August 27,2024

Measuring 'quality of life' is an important trend in cancer care

byUniversity of Rochester Medical CenterCredit: Pixabay/CC0 Public DomainAs novel cancer treatments continually emerge, it is essential to collect data on patients' quality of life along wit

Updated on:August 27,2024

US approves sickle cell breakthrough with gene editing therapy

Credit: Unsplash/CC0 Public DomainThe United States on Friday approved a breakthrough therapy that uses revolutionary gene editing tool CRISPR to treat the debilitating blood disorder sickle cell dise

Updated on: January 02,2024

US approves sickle cell breakthrough with gene editing therapy

Credit: Unsplash/CC0 Public DomainThe United States on Friday approved a breakthrough therapy that uses revolutionary gene editing tool CRISPR to treat the debilitating blood disorder sickle cell dise

Updated on:January 02,2024

Scientists find powerhouses that fight tumours from within

In recent years doctors have turned to a new treatment for cancer, immunotherapy, which works by leveraging the body's own immune system to fight tumoursLurking deep inside some tumours are "

Updated on: December 20,2023

Scientists find powerhouses that fight tumours from within

In recent years doctors have turned to a new treatment for cancer, immunotherapy, which works by leveraging the body's own immune system to fight tumoursLurking deep inside some tumours are "

Updated on:December 20,2023

Diets rich in refined fiber may increase liver cancer risk in some individuals

by Tyrel Linkhorn,University of ToledoGraphical abstract. Credit:Gastroenterology(2022). DOI: 10.1053/j.gastro.2022.08.033Many people commonly consume fiber-enriched foods to p

Updated on: December 20,2023

Diets rich in refined fiber may increase liver cancer risk in some individuals

by Tyrel Linkhorn,University of ToledoGraphical abstract. Credit:Gastroenterology(2022). DOI: 10.1053/j.gastro.2022.08.033Many people commonly consume fiber-enriched foods to p

Updated on:December 20,2023

Basic research opens up new therapeutic opportunities for fighting leukemia

byUniversity of Veterinary Medicine—ViennaGenome-wide CRISPR/Cas9-based loss-of-function screen identifies genetic dependencies of STAT3Y640F-driven cells a) Schematic illustration of a competit

Updated on: December 25,2023

Basic research opens up new therapeutic opportunities for fighting leukemia

byUniversity of Veterinary Medicine—ViennaGenome-wide CRISPR/Cas9-based loss-of-function screen identifies genetic dependencies of STAT3Y640F-driven cells a) Schematic illustration of a competit

Updated on:December 25,2023

First test of anti-cancer agent PAC-1 in human clinical trials shows promise

by Diana Yates,University of Illinois at Urbana-ChampaignProcaspase-3 (PC-3) expressions in diverse tumor histologies categorized as moderate-to-strong immunostaining intensities. Credit:B

Updated on: December 27,2023

First test of anti-cancer agent PAC-1 in human clinical trials shows promise

by Diana Yates,University of Illinois at Urbana-ChampaignProcaspase-3 (PC-3) expressions in diverse tumor histologies categorized as moderate-to-strong immunostaining intensities. Credit:B

Updated on:December 27,2023